Jul. 14 at 8:50 PM
$VSTM China’s CDE has cleared GFH375 (VS-7375) for clinical evaluation with either the pan-RAS inhibitor GFH276 or the investigational bispecific antibody GFS202A.
These additions now sit alongside a remarkably broad development architecture:
• PDAC: gemcitabine/nab-paclitaxel, gemcitabine for older patients, cetuximab, PRMT5 inhibition, and potential integration with avutometinib + defactinib (FAK/PYK2)
• NSCLC: first-line carboplatin + pemetrexed + pembrolizumab, alongside dedicated monotherapy development, including patients with untreated asymptomatic brain metastases
• CRC: cetuximab or panitumumab, plus first-line chemotherapy combinations
• Across tumors: ERAS-0015 pan-RAS molecular-glue inhibition, GFH276 pan-RAS inhibition, and GFS202A bispecific-antibody strategies
Perhaps the defining advantage of VS-7375 is therefore becoming larger than potency alone.
Combinability may ultimately define the platform.
